Nxera Pharma Co., Ltd. (FRA:JSS)

Germany flag Germany · Delayed Price · Currency is EUR
4.800
-0.100 (-2.04%)
Last updated: Feb 20, 2026, 8:08 AM CET
Market Cap444.74M -20.2%
Revenue (ttm)160.87M +2.7%
Net Income-68.07M
EPS-0.75
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,400
Average Volumen/a
Open4.800
Previous Close4.900
Day's Range4.800 - 4.800
52-Week Range4.040 - 5.850
Betan/a
RSI55.77
Earnings DateFeb 13, 2026

About Nxera Pharma

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 382
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol JSS
Full Company Profile

Financial Performance

In 2025, Nxera Pharma's revenue was 29.62 billion, an increase of 2.71% compared to the previous year's 28.84 billion. Losses were -12.53 billion, 159.0% more than in 2024.

Financial numbers in JPY Financial Statements